MYASTHENIA GRAVIS

This study tests how well nipocalimab works compared to efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which better contr…

This study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard drugs for generalized myasthenia gravis. The goal is to see if this one-time cell therapy can better control symptoms like muscle weakness and fatigue. About 66 adults who ha…

This early-stage study tests a new treatment called anito-cel for people with generalized myasthenia gravis, a condition causing muscle weakness. Anito-cel is a type of CAR-T cell therapy that targets specific immune cells to reduce disease activity. The study will enroll about 3…

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune nerve diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy that haven't responded to standard therapies. KITE-363 uses a patient's …

This study tests a drug called nipocalimab in adults with generalized myasthenia gravis, a condition that causes muscle weakness. About 199 participants will receive either the drug or a placebo to see if it improves daily activities like talking, chewing, and breathing. The goal…

This study is testing different drug combinations to find safer and more effective treatments for people with myasthenia gravis, a condition that causes muscle weakness. About 70 adults with generalized MG will try either a new drug alone or added to their current treatment. The …

This early-stage study tests a new treatment called CC-97540, which uses a patient's own immune cells (CAR T cells) to target and calm the immune system in people with multiple sclerosis or myasthenia gravis. The main goal is to check safety and find the right dose. About 120 adu…

This early-stage study tests a new treatment called CD19-BCMA CAR-T for people with refractory generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing severe weakness. The therapy uses a patient's own immune cells, modified to …

This study tests a drug called nipocalimab in children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely lowers harmful antibodies and improves daily activities. About 12 children will receive the drug,…

This study tests a new medicine called IM-101 in adults with myasthenia gravis, a disease that causes muscle weakness. The trial has two parts: first, checking safety and the right dose in people with a specific antibody type; second, testing how well it works in people with diff…

This study tests the drug rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition that causes muscle weakness. The main goal is to see if the drug improves daily activities after one treatment cycle. Participants receive the drug and are monitored for…

This study tests whether adding empasiprubart to the standard treatment efgartigimod can further improve symptoms in people with a specific type of generalized myasthenia gravis (gMG). About 70 adults who still have partial symptoms despite efgartigimod will receive the combinati…

This early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with relapsed or hard-to-treat neurological autoimmune diseases like multiple sclerosis, myasthe…

This study looks at how well a new drug called Zilucoplan works for people with myasthenia gravis, a disease that causes muscle weakness. Researchers will track 55 French patients over three months to see if the drug improves muscle strength and daily life, and check for side eff…

This study looks at whether giving the drug ravulizumab early, after standard treatments, can help people with a life-threatening myasthenia gravis crisis recover faster in the ICU. About 30 adults in France will be observed for 6 months. The goal is to see if it reduces time on …

This study tests whether aerobic exercise or cognitive behavioral therapy can reduce severe fatigue in people with myasthenia gravis, a muscle weakness disease. Researchers will compare these approaches to usual care in 60 adults with stable MG. The goal is to find practical ways…

This study tests a special exercise method using whole-body electrical muscle stimulation (WB-EMS) in adults with neuromuscular diseases like ALS, SMA, and muscular dystrophy. Because these conditions make normal exercise hard, WB-EMS directly triggers muscle contractions without…

This study tests an experimental drug called NMD670 in 84 adults with myasthenia gravis (a disease that causes muscle weakness). Participants take either NMD670 or a placebo pill twice daily for 21 days. The goal is to see if the drug improves muscle strength and daily function c…

This study looks at whether light or moderate exercise is better for adults with myasthenia gravis, a condition that causes muscle weakness. Twenty participants will join a 12-week exercise program three times a week, split into light or moderate intensity groups. The goal is to …

This study explores whether artificial intelligence can help standardize traditional Chinese medicine tongue diagnosis for myasthenia gravis, a chronic muscle weakness condition. Researchers will take tongue photos from 100 participants (50 with myasthenia gravis and 50 healthy c…

This study monitors the long-term safety of the drug efgartigimod in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. About 680 participants will be followed, some taking efgartigimod and others not, to compare risks like serious infection…

This study is creating a registry of 800 adults with Myasthenia Gravis (MG) at Yale University. Participants donate blood and stool samples, which will be used in future research to better understand MG. No treatment or intervention is provided.

This study will collect smartphone recordings from 225 people with and without myasthenia gravis to measure symptoms like slurred speech, hoarse voice, droopy eyelids, and arm fatigue. Researchers will use machine learning to see if these recordings can tell the difference betwee…

This study looks at why people with myasthenia gravis (MG) feel short of breath, even during rest or sleep. Researchers will use breathing tests, sleep studies, and questionnaires in 50 adults with MG to find the causes. The goal is to improve comfort, quality of life, and preven…

This study follows pregnant or breastfeeding women who have taken efgartigimod for myasthenia gravis or CIDP. Researchers will monitor mothers, fetuses, and infants for any health issues, including birth defects. The goal is to gather safety data, not to test a new treatment.